Gene-Disorder Association · Article
Gene
MAP2K1 Mitogen-Activated Protein Kinase Kinase 1
×
First reported
1950
Supporting publications
1
Manually curated Approved treatment annotated
Association Review
In brief The association between MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) and Hepatocellular Carcinoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
16
Compounds
2
Trials
304 of 993 via MAP2K1 compounds
Publications
1
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Hepatocellular Carcinoma
The disorder 31 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features 3 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics 2 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 993 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
1 publication
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 9 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access